Endometriosis - Pipeline Review, H1 2018

Publisher Name :
Date: 20-Mar-2018
No. of pages: 133
Inquire Before Buying

Endometriosis - Pipeline Review, H1 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Endometriosis - Pipeline Review, H1 2018, provides an overview of the Endometriosis (Women's Health) pipeline landscape.

Endometriosis is an often painful disorder in which tissue that normally lines the inside of uterus (endometrium) grows outside uterus (endometrial implant). Symptoms include pelvic pain, menstrual cramps, inflammation, infertility and abnormal bleeding. Risk factors age, uterine abnormalities, history of pelvic infection and family history. Treatment includes NSAIDs, birth control pills and progestins.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Endometriosis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Endometriosis (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Endometriosis (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Endometriosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 2, 11, 7, 1, 15, 3 and 2 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 4 and 3 molecules, respectively.

Endometriosis (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Endometriosis (Women's Health).

- The pipeline guide reviews pipeline therapeutics for Endometriosis (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Endometriosis (Women's Health) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Endometriosis (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Endometriosis (Women's Health)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Endometriosis (Women's Health).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Endometriosis (Women's Health) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Endometriosis - Pipeline Review, H1 2018

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Endometriosis - Overview 7
Endometriosis - Therapeutics Development 8
Pipeline Overview 8
Pipeline by Companies 9
Pipeline by Universities/Institutes 12
Products under Development by Companies 13
Products under Development by Universities/Institutes 16
Endometriosis - Therapeutics Assessment 17
Assessment by Target 17
Assessment by Mechanism of Action 20
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Endometriosis - Companies Involved in Therapeutics Development 27
AbbVie Inc 27
Addex Therapeutics Ltd 27
Astellas Pharma Inc 28
Bayer AG 28
ElexoPharm GmbH 29
EndoCeutics Inc 29
Enteris BioPharma Inc 30
Evotec AG 30
Forendo Pharma Ltd 31
Immunitor Inc 31
Kissei Pharmaceutical Co Ltd 31
Luye Pharma Group Ltd 32
Nippon Shinyaku Co Ltd 32
Ogeda SA 33
Philogen SpA 33
Repros Therapeutics Inc 33
SK Chemicals Co Ltd 34
Takeda Pharmaceutical Co Ltd 34
ValiRx Plc 35
Viramal Ltd 35
Endometriosis - Drug Profiles 36
acolbifene hydrochloride + GnRH Agonist + prasterone - Drug Profile 36
BAY-1128688 - Drug Profile 37
BAY-1158061 - Drug Profile 38
BAY-1817080 - Drug Profile 39
BAY-1834845 - Drug Profile 40
danazol - Drug Profile 41
Drug 1 for Endometriosis - Drug Profile 42
Drug 2 for Endometriosis - Drug Profile 43
Drug 3 for Endometriosis - Drug Profile 44
Drug 4 for Endometriosis - Drug Profile 45
Drug for Endometriosis - Drug Profile 46
Drug to Antagonize P2X3 for Endometriosis - Drug Profile 47
Drug to Inhibit C-Jun for Endometriosis - Drug Profile 48
EC-304 - Drug Profile 49
EC-313 - Drug Profile 50
elagolix sodium - Drug Profile 51
fezolinetant - Drug Profile 58
FP-5677 - Drug Profile 61
goserelin ER - Drug Profile 62
KLH-2109 - Drug Profile 63
leuprolide - Drug Profile 66
MIA-602 - Drug Profile 68
NHP-07 - Drug Profile 70
NS-580 - Drug Profile 71
opigolix - Drug Profile 72
PGL-2001 - Drug Profile 73
progesterone - Drug Profile 74
Recombinant Protein for Endometriosis, Ovarian Hyperstimulation Syndrome and Polycystic Ovarian Syndrome - Drug Profile 75
relugolix - Drug Profile 76
SKI-2670 - Drug Profile 83
Small Molecule to Antagonize FSH Receptor and LH Receptor for Women's Health - Drug Profile 84
Small Molecules to Antagonize GnRH for Endometriosis, Male Health, Oncology and Uterine Fibroids - Drug Profile 85
Small Molecules to Antagonize Prostanoid EP2 and EP4 Receptors for Endometriosis - Drug Profile 86
Small Molecules to Inhibit 17 Beta-HSD1 for Endometriosis - Drug Profile 87
Small Molecules to Inhibit 17 Beta-Hydroxysteroid Dehydrogenase Type1 for Endometriosis and Estrogen Dependent Cancers - Drug Profile 88
Small Molecules to Inhibit CD147 for Arthritis, Endometriosis, Immunology and Oncology - Drug Profile 89
Small Molecules to Inhibit HSD17B1 for Endometriosis - Drug Profile 90
SP-011 - Drug Profile 91
SP-012 - Drug Profile 92
SR-16234 - Drug Profile 93
Stem Cell Therapy for Asherman's Syndrome and Endometrial Atrophy - Drug Profile 94
Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology - Drug Profile 95
telapristone acetate - Drug Profile 96
tetravil - Drug Profile 105
TOT-206 - Drug Profile 107
triptorelin acetate ER - Drug Profile 108
V-Endo - Drug Profile 109
VAL-301 - Drug Profile 110
vilaprisan - Drug Profile 111
VPE-001 - Drug Profile 113
Endometriosis - Dormant Projects 114
Endometriosis - Discontinued Products 116
Endometriosis - Product Development Milestones 117
Featured News & Press Releases 117
Appendix 129
Methodology 129
Coverage 129
Secondary Research 129
Primary Research 129
Expert Panel Validation 129
Contact Us 129
Disclaimer 130

List of Tables
Number of Products under Development for Endometriosis, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Companies, H1 2018 (Contd..2), H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Target, H1 2018 (Contd..1), H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Endometriosis - Pipeline by AbbVie Inc, H1 2018
Endometriosis - Pipeline by Addex Therapeutics Ltd, H1 2018
Endometriosis - Pipeline by Astellas Pharma Inc, H1 2018
Endometriosis - Pipeline by Bayer AG, H1 2018
Endometriosis - Pipeline by ElexoPharm GmbH, H1 2018
Endometriosis - Pipeline by EndoCeutics Inc, H1 2018
Endometriosis - Pipeline by Enteris BioPharma Inc, H1 2018
Endometriosis - Pipeline by Evotec AG, H1 2018
Endometriosis - Pipeline by Forendo Pharma Ltd, H1 2018
Endometriosis - Pipeline by Immunitor Inc, H1 2018
Endometriosis - Pipeline by Kissei Pharmaceutical Co Ltd, H1 2018
Endometriosis - Pipeline by Luye Pharma Group Ltd, H1 2018
Endometriosis - Pipeline by Nippon Shinyaku Co Ltd, H1 2018
Endometriosis - Pipeline by Ogeda SA, H1 2018
Endometriosis - Pipeline by Philogen SpA, H1 2018
Endometriosis - Pipeline by Repros Therapeutics Inc, H1 2018
Endometriosis - Pipeline by SK Chemicals Co Ltd, H1 2018
Endometriosis - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2018
Endometriosis - Pipeline by ValiRx Plc, H1 2018
Endometriosis - Pipeline by Viramal Ltd, H1 2018
Endometriosis - Dormant Projects, H1 2018
Endometriosis - Dormant Projects, H1 2018 (Contd..1), H1 2018
Endometriosis - Discontinued Products, H1 2018

List of Figures
Number of Products under Development for Endometriosis, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
  • Global Antioxidant Vitamins Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 100
    The global Antioxidant Vitamins market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ millio......
  • Global Clavulanate Potassium Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 86
    The global Clavulanate Potassium market was valued at US$ 446.6 million in 2023 and is anticipated to reach US$ 637.2 million by 2030, witnessing a CAGR of 5.2% during The forecast period 2024-2030. North American market for Clavulanate Potassium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Clavulanate Potassium is estimated to increase from $ million in 2023......
  • Global Amoxicillin Sodium Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 84
    The global Amoxicillin Sodium market was valued at US$ 460.9 million in 2023 and is anticipated to reach US$ 735.1 million by 2030, witnessing a CAGR of 7.0% during The forecast period 2024-2030. North American market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach......
  • Global Melatonin Supplements Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 106
    The global Melatonin Supplements market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ mil......
  • Global Sleeping Pills (Prescription Drugs) Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 93
    The global Sleeping Pills (Prescription Drugs) market was valued at US$ 1022.3 million in 2023 and is anticipated to reach US$ 1437.8 million by 2030, witnessing a CAGR of 4.9% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical......
  • Global Sleeping Pills Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 94
    The global Sleeping Pills market was valued at US$ 2042.3 million in 2023 and is anticipated to reach US$ 2979.5 million by 2030, witnessing a CAGR of 3.8% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estim......
  • Global Zinc Oral Drops Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85
    The global Zinc Oral Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a......
  • Global Zinc Drops Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85
    The global Zinc Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % duri......
  • Global Anti-Infectives Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 78
    The global Anti-Infectives market was valued at US$ 22700 million in 2023 and is anticipated to reach US$ 27480 million by 2030, witnessing a CAGR of 2.3% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estima......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs